StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
INDRANIB.BO$11.49+4.91%
Fair $11.49+0.0%

INDRANIB.BO

Indrayani Biotech Limited

Industrials / Specialty Business ServicesBSE

$11.49

+0.52 (+4.91%)

Fairly Valued+0.0%Fair Value $11.49Fund rank 19/100 · Data gapFallback financials|
SA 25/D
F-Score: 0/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-272.3M · quality 27.3/100

Data gap 19/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 5/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

25/100

D

Piotroski

0/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. ROE is -8.4%, below the 5% threshold
Thesis & Journal · INDRANIB.BOLocal privado en este navegador · Indrayani Biotech Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$523M

P/E

N/A

•

EV/EBITDA

22.7x

↑

ROE

-8.4%

↓

Gross Margin

36.4%

↑

Debt/Equity

1.89

↑
52-Week Range$11
$6$17

TradingView lightweight chart

INDRANIB.BO price, volumen y niveles de valoración

Último $11.10Periodo -2.8%
Fair value: $11.49

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+28.4%

FCF CAGR

—

FCF margin

-6.2%

FCF / Net income

1.33x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.30B · net income $-61.1M · FCF $-81.2M

2022-FY → 2025-FY

Gross margin

36.4%+3.1% pts

Operating margin

3.1%-6.9% pts

Net margin

-4.7%-11.9% pts

FCF margin

-6.2%-10.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.30B$1.30B$1.66B$1.63B$615.7M
Net Income$-61.1M$-61.1M$104.2M$87.4M$44.4M
EBITDA$83.4M$83.4M$246.6M$206.5M$69.4M
EPS-0.35-0.351.402.051.30
Gross Margin36.4%36.4%41.6%37.3%33.3%
Operating Margin3.1%3.1%11.9%8.6%9.9%
Net Margin-4.7%-4.7%6.3%5.4%7.2%
Balance Sheet
Debt/Equity1.891.891.671.270.78
Cash Flow
Free Cash Flow$-81.2M$-81.2M$-468.4M$-272.3M$29.0M
Returns
ROE-8.4%-8.4%15.5%15.9%18.4%
Valuation
P/E——44.9833.7624.83
EV/EBITDA22.6722.6716.1717.8218.38
P/B0.720.724.275.464.56
Growth & Yield
Revenue Growth-21.7%-21.7%2.0%164.6%—
EPS Growth-125.0%-125.0%-31.7%58.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -33.5%

Total return

-33.5%

Start / end P/E

n/dx → n/dx

EPS bridge

1.40 → -0.35

Residual

-33.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-33.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.